# Preliminary Perturbation Analysis Report

**Query:** Which one has teh most KO effect, is it Dimethyl fumarate or CHCHD2
**Date:** 2025-11-16 22:16:17

> **Note:** This is a preliminary report generated before literature search.
> Literature search results will be added to the final comprehensive report.

---

**Total Perturbations:** 2
**Successful:** 2
**Comparison:** ✓ Generated (76 shared pathways)

---

## Perturbation 1: CHCHD2 (gene)

## Methods

This analysis was performed using the Virtual Cell system, which integrates:
- **Differential Expression Analysis:** RNA-seq data analysis
- **Pathway Enrichment:** GSEA (Gene Set Enrichment Analysis) and PSEA (Pathway Set Enrichment Analysis)
- **Literature Integration:** Edison Scientific RAG system (PaperQA) for evidence retrieval
- **Hypothesis Generation:** Mechanistic hypothesis generation with literature support

## Key Results

**Differential Expression:** 384 significantly differentially expressed genes (p ≤ 0.05) out of 1950 total genes

**Top Upregulated Genes:**
1. **DHRS4**: log2FC=1.19, p=7.003e-03, p_adj=1.000 (perturbed: 0.30, control: 0.13)
2. **GPAM**: log2FC=1.08, p=3.399e-03, p_adj=1.000 (perturbed: 0.44, control: 0.21)
3. **EPB41**: log2FC=1.07, p=4.380e-04, p_adj=0.854 (perturbed: 0.63, control: 0.30)
4. **MFSD4B**: log2FC=1.02, p=4.454e-03, p_adj=1.000 (perturbed: 0.46, control: 0.23)
5. **SCD**: log2FC=0.96, p=3.626e-04, p_adj=0.707 (perturbed: 0.81, control: 0.41)
6. **NUDT4**: log2FC=0.94, p=2.316e-05, p_adj=0.045 (perturbed: 1.11, control: 0.58)
7. **TRAPPC6B**: log2FC=0.92, p=2.501e-04, p_adj=0.488 (perturbed: 0.89, control: 0.47)
8. **GALNT10**: log2FC=0.92, p=2.351e-05, p_adj=0.046 (perturbed: 1.18, control: 0.63)
9. **GK5**: log2FC=0.89, p=2.287e-03, p_adj=1.000 (perturbed: 0.68, control: 0.37)
10. **ERCC6**: log2FC=0.88, p=1.101e-02, p_adj=1.000 (perturbed: 0.49, control: 0.27)

**Top Downregulated Genes:**
1. **CYCS**: log2FC=-0.05, p=4.100e-02, p_adj=1.000 (perturbed: 5.88, control: 6.09)
2. **RAB5IF**: log2FC=-0.05, p=1.488e-02, p_adj=1.000 (perturbed: 5.91, control: 6.14)
3. **CEBPB**: log2FC=-0.08, p=2.343e-03, p_adj=1.000 (perturbed: 5.71, control: 6.05)
4. **LAPTM4A**: log2FC=-0.11, p=4.750e-02, p_adj=1.000 (perturbed: 4.29, control: 4.62)
5. **MT2A**: log2FC=-0.13, p=4.350e-06, p_adj=0.008 (perturbed: 6.51, control: 7.11)
6. **NEAT1**: log2FC=-0.13, p=8.968e-03, p_adj=1.000 (perturbed: 4.67, control: 5.12)
7. **GSTO1**: log2FC=-0.13, p=7.313e-03, p_adj=1.000 (perturbed: 4.50, control: 4.94)
8. **CTSD**: log2FC=-0.14, p=3.723e-02, p_adj=1.000 (perturbed: 4.07, control: 4.47)
9. **HLA-C**: log2FC=-0.15, p=7.583e-13, p_adj=0.000 (perturbed: 5.92, control: 6.58)
10. **SLC20A1**: log2FC=-0.17, p=3.203e-02, p_adj=1.000 (perturbed: 3.52, control: 3.95)


![Volcano Plot](/home/nebius/cellian/llm/perturbation_outputs/gene_CHCHD2/volcano.png)

**Pathway Enrichment:** 8 significantly enriched pathways (p ≤ 0.05)

Top enriched pathways:
1. Phospholipase D signaling pathway (NES=1.59, p=2.222e-02, FDR=0.332)
2. Sphingolipid signaling pathway (NES=1.59, p=1.667e-02, FDR=0.273)
3. Thyroid hormone signaling pathway (NES=1.59, p=1.613e-02, FDR=0.229)
4. Fanconi anemia pathway (NES=1.58, p=1.754e-02, FDR=0.225)
5. Insulin signaling pathway (NES=1.56, p=3.509e-02, FDR=0.229)
6. Chronic myeloid leukemia (NES=1.55, p=3.509e-02, FDR=0.174)
7. Adrenergic signaling in cardiomyocytes (NES=1.45, p=4.615e-02, FDR=0.309)
8. Small cell lung cancer (NES=1.41, p=3.846e-02, FDR=0.292)

![Pathway Enrichment](/home/nebius/cellian/llm/perturbation_outputs/gene_CHCHD2/pathway_enrichment.png)


![RNA GSEA Enrichment Plot](/home/nebius/cellian/llm/perturbation_outputs/gene_CHCHD2/rna_gsea.png)


![Protein/PPI PSEA Enrichment Plot](/home/nebius/cellian/llm/perturbation_outputs/gene_CHCHD2/protein_psea.png)

## Limitations & Notes

- **Computational Predictions:** This analysis is based on computational predictions and requires experimental validation.
- **Literature Evidence:** Literature support classification is automated and should be manually reviewed for critical hypotheses.
- **Tissue/Cell Context:** Results are specific to the analyzed cell type and may not generalize to other contexts.
- **Dynamic Processes:** This analysis represents a snapshot and does not capture temporal dynamics of cellular responses.

---

*Report generated by Virtual Cell system*


---

## Perturbation 2: [('Dimethyl fumarate', 5.0, 'uM')] (drug)

## Methods

This analysis was performed using the Virtual Cell system, which integrates:
- **Differential Expression Analysis:** RNA-seq data analysis
- **Pathway Enrichment:** GSEA (Gene Set Enrichment Analysis) and PSEA (Pathway Set Enrichment Analysis)
- **Literature Integration:** Edison Scientific RAG system (PaperQA) for evidence retrieval
- **Hypothesis Generation:** Mechanistic hypothesis generation with literature support

## Key Results

**Pathway Enrichment:** 3 significantly enriched pathways (p ≤ 0.05)

Top enriched pathways:
1. Wnt signaling pathway (NES=-1.66, p=1.111e-02, FDR=1.000)
2. Signaling pathways regulating pluripotency of stem cells (NES=-1.53, p=2.299e-02, FDR=1.000)
3. Huntington disease (NES=1.29, p=5.000e-02, FDR=0.861)

![Pathway Enrichment](/home/nebius/cellian/llm/perturbation_outputs/drug_[__Dimethyl fumarate_, 5.0, _uM__]/pathway_enrichment.png)

## Limitations & Notes

- **Computational Predictions:** This analysis is based on computational predictions and requires experimental validation.
- **Literature Evidence:** Literature support classification is automated and should be manually reviewed for critical hypotheses.
- **Tissue/Cell Context:** Results are specific to the analyzed cell type and may not generalize to other contexts.
- **Dynamic Processes:** This analysis represents a snapshot and does not capture temporal dynamics of cellular responses.

---

*Report generated by Virtual Cell system*


---

## Comparison Analysis

**Comparison:** Perturbation 1 vs Perturbation 2

### Shared Pathways (76)

- **Measles**: Perturbation 1 NES=0.85, Perturbation 2 NES=-0.68 (stronger: CHCHD2)
- **Wnt signaling pathway**: Perturbation 1 NES=1.28, Perturbation 2 NES=-1.66 (stronger: [('Dimethyl fumarate', 5.0, 'uM')])
- **Gastric cancer**: Perturbation 1 NES=1.28, Perturbation 2 NES=-0.90 (stronger: CHCHD2)
- **FoxO signaling pathway**: Perturbation 1 NES=-0.99, Perturbation 2 NES=-0.89 (stronger: CHCHD2)
- **Chemokine signaling pathway**: Perturbation 1 NES=1.11, Perturbation 2 NES=-0.67 (stronger: CHCHD2)
- **Breast cancer**: Perturbation 1 NES=1.29, Perturbation 2 NES=-0.91 (stronger: CHCHD2)
- **Human T-cell leukemia virus 1 infection**: Perturbation 1 NES=-0.49, Perturbation 2 NES=-0.95 (stronger: [('Dimethyl fumarate', 5.0, 'uM')])
- **Focal adhesion**: Perturbation 1 NES=1.04, Perturbation 2 NES=-0.61 (stronger: CHCHD2)
- **MAPK signaling pathway**: Perturbation 1 NES=1.10, Perturbation 2 NES=-1.17 (stronger: [('Dimethyl fumarate', 5.0, 'uM')])
- **cGMP-PKG signaling pathway**: Perturbation 1 NES=1.18, Perturbation 2 NES=-1.05 (stronger: CHCHD2)
- **Phospholipase D signaling pathway**: Perturbation 1 NES=1.59, Perturbation 2 NES=-1.00 (stronger: CHCHD2)
- **Transcriptional misregulation in cancer**: Perturbation 1 NES=-0.70, Perturbation 2 NES=-1.16 (stronger: [('Dimethyl fumarate', 5.0, 'uM')])
- **Leukocyte transendothelial migration**: Perturbation 1 NES=1.15, Perturbation 2 NES=1.25 (stronger: [('Dimethyl fumarate', 5.0, 'uM')])
- **Herpes simplex virus 1 infection**: Perturbation 1 NES=1.16, Perturbation 2 NES=-1.17 (stronger: [('Dimethyl fumarate', 5.0, 'uM')])
- **Prostate cancer**: Perturbation 1 NES=1.40, Perturbation 2 NES=-0.77 (stronger: CHCHD2)
- **Endocytosis**: Perturbation 1 NES=-0.64, Perturbation 2 NES=-1.58 (stronger: [('Dimethyl fumarate', 5.0, 'uM')])
- **AGE-RAGE signaling pathway in diabetic complications**: Perturbation 1 NES=1.69, Perturbation 2 NES=-0.83 (stronger: CHCHD2)
- **Yersinia infection**: Perturbation 1 NES=0.66, Perturbation 2 NES=-0.57 (stronger: CHCHD2)
- **Axon guidance**: Perturbation 1 NES=1.26, Perturbation 2 NES=-1.05 (stronger: CHCHD2)
- **Lipid and atherosclerosis**: Perturbation 1 NES=1.06, Perturbation 2 NES=-0.79 (stronger: CHCHD2)

### Summary

## Comparison Summary

**Comparison: CHCHD2 vs [('Dimethyl fumarate', 5.0, 'uM')]**

### Pathway Effects

- **Measles**: CHCHD2 activation (NES 0.85), [('Dimethyl fumarate', 5.0, 'uM')] repression (NES -0.68)
- **Wnt signaling pathway**: CHCHD2 activation (NES 1.28), [('Dimethyl fumarate', 5.0, 'uM')] repression (NES -1.66)
- **Gastric cancer**: CHCHD2 activation (NES 1.28), [('Dimethyl fumarate', 5.0, 'uM')] repression (NES -0.90)
- **FoxO signaling pathway**: Both repression, but CHCHD2 is stronger (NES -0.99 vs -0.89)
- **Chemokine signaling pathway**: CHCHD2 activation (NES 1.11), [('Dimethyl fumarate', 5.0, 'uM')] repression (NES -0.67)
- **Breast cancer**: CHCHD2 activation (NES 1.29), [('Dimethyl fumarate', 5.0, 'uM')] repression (NES -0.91)
- **Human T-cell leukemia virus 1 infection**: Both repression, but [('Dimethyl fumarate', 5.0, 'uM')] is stronger (NES -0.49 vs -0.95)
- **Focal adhesion**: CHCHD2 activation (NES 1.04), [('Dimethyl fumarate', 5.0, 'uM')] repression (NES -0.61)
- **MAPK signaling pathway**: CHCHD2 activation (NES 1.10), [('Dimethyl fumarate', 5.0, 'uM')] repression (NES -1.17)
- **cGMP-PKG signaling pathway**: CHCHD2 activation (NES 1.18), [('Dimethyl fumarate', 5.0, 'uM')] repression (NES -1.05)

## LLM-Generated Mechanistic Hypotheses

> **Status:** Hypotheses generated using LLM analysis of all combined results.
> **Literature Search:** Running in background... Results will be added to final report.

### Hypothesis 1: "statement": "CHCHD2 perturbation by Dimethyl fumarate leads to decreased RFX5 expression, subsequently impairing downstream thyroid hormone signaling.",

**Literature Support:** *Pending... Literature search in progress.*

---

### Hypothesis 2: "statement": "CHCHD2 perturbation by Dimethyl fumarate activates Phospholipase D signaling, contributing to increased insulin signaling.",

**Literature Support:** *Pending... Literature search in progress.*

---

### Hypothesis 3: "statement": "Dimethyl fumarate treatment targeting CHCHD2 downregulates Wnt signaling, potentially inhibiting the pluripotency of stem cells.",

**Literature Support:** *Pending... Literature search in progress.*

---

### Hypothesis 4: "statement": "CHCHD2 perturbation by Dimethyl fumarate activates sphingolipid signaling to influence adrenergic signaling in cardiomyocytes, potentially affecting heart function.",

**Literature Support:** *Pending... Literature search in progress.*

---

---

## Next Steps

1. Literature search is running for all generated hypotheses
2. Final comprehensive report will include:
   - Full paper citations with links
   - Literature support classification
   - Supporting evidence for each hypothesis

*Preliminary report generated by Virtual Cell system*
